Articles On Cann Group (ASX:CAN)

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

The ACIC says weed consumption increased in cities and regions ROO receives USA design patent approval for its Heat Exchange Probe EMD has launched its second ultra-pure CBD capsule, the EMD-RX7   The latest Australian Criminal Intelligen...

Cann Group (CAN) receives the necessary permit by the Office of Drug Control (ODC) to allow commercial cultivation activities of medicinal cannabis to commence in its new state-of-the-art production facility near Mildura, Victoria. The OD...

Clinuvel releases positive preliminary results from pilot study Cann’s Mildura cannabis facility is ready Imugene signs deal with Merck Respiri provides wheezo to children’s hospital in Michigan The ASX 200 Health Index (XHJ) is trading l...

Three years after first acquiring the site in Mildura in Victoria, Australian medicinal cannabis company Cann Group (ASX: CAN) has been given permission to cultivate the drug at the now-completed, high-tech facility. The Office of Drug Con...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

Hemp farmers in New York have been given the go ahead to plant cannabis for the 2022 season. The legislation allows conditionally licensed cannabis farmers to grow weed, but they must meet certain requirements, including safe, sustainable a...

At the time of writing, the ASX 200 Health Index (XHJ) is up by another 3.3%, while the benchmark ASX 200 has risen by 0.5%. Cancer and fibrosis focused biotech Amplia Therapeutics (ASX:ATX) said its AMP945 drug improves effectiveness of cu...

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

Cann Group (CAN) is set to begin recruitment for its phase three clinical trial assessing its CBD treatment for sleep disturbances At least 212 patients will be randomly placed into four cohorts receiving one of three different doses of th...

Key points ASX cannabis shares could benefit from new COVID-fighting research Cannabidiol (CBD) has proven effective in mice Researchers hope to launch human trials ASX cannabis shares haven’t exactly shot the lights out over the past f...

US stocks continue slide despite strong GDP Wall Street moved further down into correction territory, despite the US recording its strongest economic growth in almost 40 years. The US GDP expanded at a quarterly increase of 1.7% or an annua...

In December France banned the sale of hemp flower and leaf loaded with CBD, but the Conseil d’Etat provisionally overruled the decision on Wednesday – pending further examination of the order. Basically, the French court said that flowers...

Cann Group (CAN) receives a GMP licence from the Therapeutic Goods Administration (TGA) to manufacture therapeutic goods for its Southern facility This licence enables the company to manufacture Active Pharmaceutical Ingredient (API) and m...

Medicinal cannabis stock Cann Group (ASX:CAN) has scored a regulatory milestone, after being granted a GMP licence to manufacture CBD therapeutic goods in its Southern facility in Victoria. The GMP (or Good Manufacturing Practice) license w...

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

The Australian medicinal cannabis market has seen strong growth in 2021, with revenue from product sales estimated at $230 million. And medical cannabis prescriptions are at an all-time high. The TGA said 13,666 Australian patients were app...

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

Uber is expanding its horizons, with plans to allow users to order cannabis on its Uber Eats app. Next week the app will list cannabis retailer Tokyo Smoke on its marketplace and customers will be able to place orders on the app – but they...

Instead of a chocolate advent calendar this year, Californians can get their hands on a cannabis calendar with edibles, prerolls, grams of flower and four days of cannabis accessories. “We’ve seen the success of unique advent calendars in o...

Actor Jim Belushi has partnered with – you guessed it – Dan Aykroyd on a tour through Oklahoma’s cannabis industry ahead of a Blues Brothers performance. “We believe that cannabis is one of the great, great medicines that can lead to a path...

ASX cannabis shares were once one of the hottest sectors with no shortage of new pot stocks hitting the market. The Cann Group Ltd (ASX: CAN) share price, for example, skyrocketed almost 300% between September 2017 and January 2018 amid t...

Last week California Governor Gavin Newsom signed Assembly Bill (AB-45), formally permitting the sales of hemp-derived CBD products in the state. Hemp has been legalised at the US federal level since 2018, but state agencies have been slow...

Retail giant Amazon has rejigged its cannabis policy, allowing employees who were previously fired for testing positive for marijuana to reapply for jobs. The company has now excluded marijuana from its comprehensive pre-employment drug scr...

Just under two years since Otto Buttula became chairman of Rhythm Biosciences (ASX:RHY), it has gained over 500% since – and the boss of the high flying biotech just chipped more in. Buttula, who in the past has headed financial services fi...

The Boston Beer Company (NYSE:SAM) is set to launch a new range of non-alcoholic cannabis-infused drinks in Canada with the help of Australian listed Althea Group Holdings’ (ASX:AGH) subsidiary. Peak processing Solutions will research and d...

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

Virginia is the latest US state to legalise marijuana and they’re celebrating with the first annual CannaFest VA cannabis trade show on September 19. The event will feature a concert, and a custom car and motorcycle exhibition but no, you c...

ASX cannabis shares put in a mixed performance in the 2021 financial year (FY21). Of the 9 stocks broadly falling into the ‘ASX cannabis share’ category, 6 saw their share prices fall while 3 gained in FY21. Creso Pharma Ltd (ASX: CPH) was...

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

Cannabis giants Emyria Limited (ASX:EMD) and Cann Group Limited (ASX:CAN) have parted ways. The companies originally had an agreement for the planned registration of a schedule 3 (S3) over-the-counter cannabidiol (CBD) medicine product with...

Massachusetts based cannabis operator MariMed has just announced a joint collaboration with the legendary Boston ice cream brand Emack & Bolio’s® to create a line-up of cannabis-infused vegan and dairy ice cream. The ice cream will cont...

If you’ve been watching the recent price action in lithium stocks, this week’s edition of Hot Money may not come as a huge surprise. Each week, Stockhead recaps ASX stocks that are “running hot” as deduced by the Relative Strength Index (RS...

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

Each week, Stockhead recaps ASX stocks that are “running hot” as deduced by the Relative Strength Index (RSI). The RSI is a technical gauge which measures how trading momentum is affecting the price action. A reading of 70 is seen as the le...

The Community College of Denver (CCD) has just launched a cannabis business program in Colorado. The new program offers students the opportunity to earn an Associate of Applied Science degree designed to prepare them to become business mana...

Summary The S&P/ASX200 ended lower by just 10 basis points at 7,394.30, shedding early gains. The index gained 0.3% to hit an all-time high of 7,417.60 during the day’s trade. Material sector emerged as the best performer, settlin...

The stock is down 14.47% at time of writing, falling substantially as management revealed a decent quarterly result and plans for a fresh capital raise. The post Cann Group Shares Fall 14% as It Releases Quarterly Update appeared first on M...

Languishing pot stock Cann Group Ltd [ASX:CAN] is being punished by investors today. The CAN share price is down 14.47% at time of writing, falling substantially as management revealed a decent quarterly result and plans for a fresh capital...

The ASX clawed back initial gains to start the week, closing virtually flat today. The ASX 200 closed at 7,394 which was neck and neck with the point it closed at on Friday despite gaining as much as 0.3% in early trade. Meanwhile, the ASX...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a small gain. At the time of writing, the benchmark index is up 0.1% to 7,400.7 points. Four ASX shares that have failed to follow the market higher today are...

Summary The benchmark index, S&P/ASX200, gained as much 0.3% to hit an all-time high of 7,417.60. BHP shares rose 1.8% to hit 52-week high on deal with Westshore Terminals Investment. Shares of Best & Less Group Holdings surge...

With construction of its state-of-the-art cultivation facility now underway in Mildura, medicinal cannabis company Cann Group (ASX: CAN) is rattling the tin again to bolster production capacity as market opportunities grow in Europe and Aus...

Summary The ASX 200 has continued its momentum in the opening session, making a record high. All three major US stock indices also closed at an all-time high on Friday after a volatile week. Metals X Limited is planning to recommence...

ASX 200 health stocks index rose by 0.68% this morning, compared to the broader index which rose by 0.24%. Respiratory device specialist, 4D Medical (ASX:4DX), led the pack, rising by 7%. In its quarterly update,  the company said it has ra...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

The Cann Group Ltd (ASX: CAN) share price is crashing lower on Monday morning. This follows the announcement of yet another capital raising by the cannabis company. At the time of writing, the Cann share price is down 14% to 32.5 cents. Wh...